When it comes to deploying AI technologies, there are both technical and ethical considerations – in healthcare, given the critical and sensitive data and decisions at play, these can be magnified nearly exponentially. Jen is joined by Vynamic’s A

On November 6th, Donald Trump was announced as the 47th President of the United States, returning to the White House for his second term. In this episode, Jen, Mindy, and Ryan discuss the potential changes to the healthcare industry that Republica

Last month, Life Sciences marketing, commercial and medical leaders from across the country gathered at Reuter’s Pharma Customer Engagement to address current challenges and share industry best practices. In this episode, Jen is joined by Vynamic’

With the first round of CMS price negotiations behind us, and the next list of targets to be released in February 2026, it’s clear that theorized implications from the Inflation Reduction Act are becoming realities for the life sciences industry.

With increasing pressure to bring products to market faster than ever, Life Sciences companies need to balance supply chain speed with global complexities, regulatory hurdles, and digital integration to maintain competitiveness. In this episode, J

Organizational AI adoption has dramatically increased over the years largely due to generative AI, leaving organizations to navigate challenges while rapidly scaling and adopting new technologies. In this episode, Jen is joined by Vynamic’s Chris

In today’s competitive and dynamic pharmaceutical landscape, mastering the art of brand planning and management is crucial to success. In this episode, Jen and Mindy are joined by Vynamic’s Brand Strategy Offering Lead, Liza Flaherty, to discuss

Two years after the announcement that Veeva and Salesforce would part ways, Life Sciences organizations are racing to evaluate their options and select their CRM partner before the 2025 cutover. Jen is joined by Vynamic’s Life Sciences Commercial

In this episode, Jen, Mindy, and Ryan discuss recent newsworthy items, including the Supreme Court’s overturning of Chevron Deference and what this will mean for the health industry, as well as strategic shifts made by Walgreens under their new CE

One of the advantages of serving clients across multiple geographies is that Vynamic can see firsthand how the differences in health systems play out in terms of spend, outcomes, and innovation. Jen & Ryan are joined by Vynamic London’s Oliver